Advances in glucagon like peptide-2 therapy. physiology, current indications and future directions
sciencedirect.com shows its articles on its own site.
Read the article on sciencedirect.com ↗Article · Aug 2018 · 1 min read
In brief
In brief
Review of GLP-2 physiology and teduglutide therapy for pediatric short bowel syndrome and intestinal failure. Discusses how this enteric hormone regulates intestinal adaptation, allowing patients to transition off parenteral nutrition, with current indications and future therapeutic applications in children.
Written by the GCMD Library team from the article.
Publication date: August 2018
Source: Seminars in Pediatric Surgery, Volume 27, Issue 4
Author(s): D.L. Sigalet
Abstract
The treatment paradigm for pediatric patients with short bowel syndrome (SBS) and intestinal failure (IF) has changed significantly over recent years; the development of dedicated IF teams, refinements in PN and surgical treatments have greatly improved survival. The majority of SBS patients undergo intestinal adaptation such that nutrient absorption from enteral feeds increases and the child can come off of PN. This “adaptation” or upregulation in nutrient absorptive capacity is still poorly understood; the enteric hormone Glucagon like peptide 2 (GLP-2) appears to be a key regulator in this process. The development of Teduglutide, a long acting GLP-2 ligand as a therapy to specifically enhance adaptation has been anticipated as a further shift in the paradigm. This article reviews the physiology of GLP-2 with an emphasis on the known or potential roles in infants and children with SBS and IF. The results and implications of the present studies and approved indications for GLP-2 and its ligands are discussed. Finally, the potential future uses of GLP-2 ligands in the pediatric population are considered.